Revance Therapeutics reported $51.12M in Selling and Administration Expenses for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Abbvie ABBV:US $ 2.98B 99M
Adamas Pharmaceuticals ADMS:US 29.73M 579K
Aerie Pharmaceuticals AERI:US $ 34.66M 114K
ALKERMES ALKS:US 136.21M 2.97M
Biodelivery Sciences International BDSI:US $ 25.47M 311K
Bristol Myers Squibb BMY:US $ 1.79B 95M
Cara Therapeutics CARA:US $ 5.88M 262K
Coherus Biosciences CHRS:US $ 39.92M 420K
Eli Lilly And LLY:US $ 1.58B 107.8M
Endo International Ordinary Shares ENDP:US 241.92M 70.98M
Flexion Therapeutics FLXN:US $ 26.99M 423K
Gw Pharmaceuticals GWPH:US 101.05M 2.71M
Horizon Pharma HZNP:US 360.26M 5.06M
JAZZ PHA JAZZ:US 363.68M 65.35M
Johnson & Johnson JNJ:US $ 6B 73M
Merk MRK:US $ 2.27B 9M
Neurocrine Biosciences NBIX:US $ 154.6M 11.4M
Pacira Pharmaceuticals PCRX:US $ 48.81M 2.01M
Procter & Gamble PG:US $ 4.95B 665M
Revance Therapeutics RVNC:US $ 51.12M 2.11M
Supernus Pharmaceuticals SUPN:US $ 72.03M 2.5M
Teva Pharmaceutical Industries TEVA:US 864M 32M
Zogenix ZGNX:US $ 39.56M 5.68M